This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should SPDR S&P 600 Small Cap ETF (SLY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SLY
Should iShares Core S&P SmallCap ETF (IJR) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJR
Should Vanguard S&P SmallCap 600 ETF (VIOO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VIOO
Catalent's (CTLT) Latest Facility Expansion to Boost Capacity
by Zacks Equity Research
Catalent's (CTLT) latest site expansion is expected to significantly boost its business.
Reasons to Retain Catalent (CTLT) Stock in Your Portfolio
by Zacks Equity Research
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.
What's in the Cards for Medtronic (MDT) in Q4 Earnings?
by Zacks Equity Research
Medtronic's (MDT) Cardiovascular business is expected to have gained share in both high and low power devices in Q4.
Reasons to Retain DaVita (DVA) Stock in Your Portfolio For Now
by Zacks Equity Research
Investors remain optimistic about DaVita (DVA) due to strength in its DaVita Kidney Care and impressive overseas growth.
Catalent's (CTLT) New Launch to Enhance Gene Therapy Development
by Zacks Equity Research
Catalent's (CTLT) latest launch is expected to provide a reliable, reproducible and scalable path to clinic to its customers.
NextGen Healthcare (NXGN) Q4 Earnings Miss Mark, Revenues Beat
by Zacks Equity Research
NextGen Healthcare's (NXGN) fiscal fourth-quarter earnings reflect strength in its Recurring revenues.
Reasons to Add Patterson Companies (PDCO) Stock to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.
AMN Healthcare's (AMN) New Buyout to Aid Healthcare Staffing
by Zacks Equity Research
AMN Healthcare's (AMN) acquisition of Connetics USA is expected to significantly boost its Nurse and Allied Solutions segment globally.
Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio For Now
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Doximity (DOCS) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Doximity's (DOCS) fiscal fourth-quarter results are likely to reflect continued strength in its telehealth platform.
Inogen (INGN) Stock Inches Up 0.5% Post Q1 Earnings Beat
by Zacks Equity Research
Inogen's (INGN) first-quarter results benefit from higher revenues across the majority of its geographical segments and categories.
OPKO Health (OPK) Post In-Line Q1 Earnings, Revenues Top
by Zacks Equity Research
OPKO Health's (OPK) first-quarter results benefit from continued strength in its Pharmaceuticals segment.
Amedisys (AMED) New Buyouts Aid Growth, Margin Pressure Stays
by Zacks Equity Research
Amedisys' (AMED) newly-formed high-acuity care segment experiences solid momentum in the first quarter.
Shockwave Medical (SWAV) Beats on Q1 Earnings & Revenues
by Zacks Equity Research
Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and expansion in gross margin.
Allscripts' (MDRX) Stock Falls 8.8% Post Q1 Earnings Miss
by Zacks Equity Research
Allscripts' (MDRX) robust Q1 results demonstrate strength in both segments.
Glaukos (GKOS) Stock Falls 25.9% Despite Q1 Earnings Beat
by Zacks Equity Research
Glaukos' (GKOS) soft Q1 results fail to impress investors.
Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Fresenius Medical's (FMS) first-quarter earnings benefit from strong performance across all the geographic regions and segments.
DENTSPLY SIRONA (XRAY) Reports Weak Q1 Preliminary Results
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) preliminary first-quarter 2022 results reflect weakness in segments.
Nevro (NVRO) Stock Falls 19% Despite Q1 Earnings Beat
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q1 partly due to soft domestic performance.
AMN Healthcare (AMN) Q1 Earnings, Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) robust Q1 results demonstrate its segmental strength.
McKesson (MCK) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter 2022 results benefit from segmental growth.
Inari Medical (NARI) Down 16.9% Despite Q1 Earnings Beat
by Zacks Equity Research
Inari Medical's (NARI) first-quarter results benefit from significant progress made across all of its growth drivers.